ZEN Graphene Solutions Develops Novel Graphene-Based Potential Treatment for Bacterial and Viral Infections in Humans Zen Graphene Solutions Ltd. is pleased to announce that it has developed a potential graphene-based antibiotic, antiviral and antifungal compound. Recently received testing results from the University Health NetworkMount Sinai Hospital Department of Microbiology in Toronto indicate that this patent pending formulation could be a medical breakthrough in the treatment of numerous human-contracted pathogens including, … Zen Graphene Solutions Ltd. (TSXV: ZEN) (OTC Pink: ZENYF) (“ZEN” or the “Company”) is pleased to announce that it has developed a potential graphene-based antibiotic, antiviral and antifungal compound. Recently received testing results from the University Health NetworkMount Sinai Hospital Department of Microbiology in Toronto indicate that this patent pending formulation could be a medical breakthrough in the treatment of numerous human-contracted pathogens including, upper and lower respiratory tract infections – where COVID-19 is a major contributor – as well as drug resistant organisms. Testing was conducted by Dr. Tony Mazzulli, MD, FRCPC, FACP, Microbiologist-in-Chief & Infectious Disease Specialist at Mount Sinai Hospital. Dr. Mazzulli is also a Professor at the Departments of Laboratory Medicine & Pathobiology and Medicine at the University of Toronto.